David Hose is a bioterrorism casualty. Little wonder, then, that his confidence in U.S. readiness for another such attack is about as low as his energy and as weak as his still-battered...
SAN FRANCISCO — David Hose is a bioterrorism casualty.
Little wonder, then, that his confidence in U.S. readiness for another such attack is about as low as his energy and as weak as his still-battered immune system, lingering aftereffects of the anthrax he accidentally inhaled while handling a letter addressed to Sen. Patrick Leahy three years ago.
“I was worried before the attacks,” said Hose, 60, who spent more than two weeks in the hospital with the anthrax infection and will never fully recover. “Now, I’m convinced it will happen again, and I don’t think we’re doing enough to address that.”
Hose, a government worker, is not alone. Biological-weapons experts, including a scientist who played a big role in eradicating smallpox from the globe, have similar concerns.
Most Read Stories
- Woman, 71, lost in Olympics with dog, built shelter, ate ants
- 3 teens killed in Lynnwood crash from Mill Creek high school
- Foreign buyers drop off as Seattle housing market hits hottest tempo since 2006 bubble
- What drivers can and cannot do under Washington state's new distracted-driving law
- Are Seattle housing prices headed for a crash? | Jon Talton
While the experts laud the increased spending government lavished on combating biological threats in 2004, they sense momentum slowing as public attention and political will wane.
The unsolved anthrax attacks that killed five and sickened Hose and 16 others three years ago are but faint background noise in the national-security debate today.
The fact that U.S. forces in Iraq have yet to find any biological weapons also factors into the public’s fading attention, experts say.
“There is a certain element of complacency setting in,” said Dr. D.A. Henderson of the University of Pittsburgh’s Center for Biosecurity. “Anthrax still keeps me up at night.”
Henderson said anthrax remains atop his list of diseases with the potential to be used as weapons. That’s because there has been little accounting of what became of the former Soviet Union’s vast biological-weapons program.
“The Russians kept 30 metric tons of anthrax in dry storage. The amount used in the U.S. attacks was 10 grams,” Henderson said.
“There were 60,000 Russians working on this, we don’t know where most of them are today.”
Henderson, who led the global smallpox-eradication campaign in the 1960s and served as a bioterrorism consultant to President Bush, said the federal government made significant progress in 2004 in combating the threat, including earmarking a record amount of money to address the problem.
Federal spending has increased from $414 million in fiscal year 2001 to a proposed $7.6 billion for this year, according to a Pitt study. Since Sept. 11, 2001, the federal government has awarded contracts worth a combined $1.5 billion to biotech companies to beef up the nation’s smallpox and anthrax vaccine stockpiles.
New lines of communications
Further, Henderson said, communications among federal agencies and local emergency officials have dramatically improved, though room for additional advances remains. Public-health officials, for instance, now monitor pharmacies for spikes in sales of fever reducers, rash ointments and other indications that a biological attack is under way.
Nonetheless, the United States remains woefully unprepared for another attack, Henderson and other experts say.
The threat from biological weapons has outstripped that from chemical and nuclear arms because of the “riotous” progress of biotechnology, according to a British Medical Association report released in October.
Careless stewardship of biotechnology advances could be exploited by terrorists to target specific ethnic groups and re-create devastating diseases such as the 1918 flu epidemic, the report says.
Another study, compiled by a panel of experts convened by the CIA in 2003 and titled “The Darker Bioweapons Future,” warned that advances in biotechnology could lead to a generation of biological weapons far more dangerous than those currently known.
“The effects of some of these engineered biological agents could be worse than any disease known to man,” the panel told the CIA. “The same science that may cure some of our worst diseases could be used to create the world’s most frightening weapons.”
In November, an influential committee of the World Health Organization recommended that researchers be permitted to conduct genetic-engineering experiments with the smallpox virus. Some bioterrorism experts, Henderson among them, consider such tinkering more hazardous than the problem it aims to combat. Henderson advocates destroying the last two known stocks of smallpox in the United States and in the former Soviet Union.
Meanwhile, public-health experts say one glaring weakness is that most cash-strapped U.S. hospitals would be unable to handle the crush of people who would be either sickened or panicked by a bioattack.
“We have incredibly undertrained public-health officials, and the numbers are getting worse,” said Dr. Shelley Hearne, executive director of the Trust for America’s Health in Washington, D.C.
“We’ve had a series of some really scary wake-up calls over how seriously unprepared we are in the case of a serious disease outbreak.”
Another major vulnerability is the nation’s antiquated vaccine-manufacturing system and the reluctance of big pharmaceutical companies to enter a low-profit, high-risk market.
Hearne pointed to Emeryville, Calif.-based Chiron’s failure to deliver half the nation’s expected flu vaccine supply in the fall and the administration’s bungled program in 2003 to inoculate 500,000 frontline health-care workers with the smallpox vaccine.
Only about 40,000 workers ultimately received injections because of apathy or health concerns over the effectiveness of the smallpox vaccine.
“We need a credible bioterrorism game plan that everybody buys into,” Hearne said. “We don’t have that.”